Lexology November 30, 2023
Axinn Veltrop & Harkrider LLP

I’m not saying that anyone from the Biden administration was reading my blog post last week on drug shortages, and maybe it’s just a coincidence that the White House announced new efforts to strengthen supply chains less than a week after my post! But, for the first meeting of the new White House Council on Supply Chain Resilience, the administration announced plans to, among other things, use the Defense Production Act to have more essential medicines made within the United States. In fact, $35 million has been identified by HHS to invest in the domestic production of key starting materials in certain sterile injectables. In addition, HHS is designating a new Supply Chain Resilience and Shortage Coordinator to address shortages...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Congress / White House, Govt Agencies, HHS, Pharma, Pharma / Biotech, Supply Chain, Technology
Federal research cuts could worsen infectious disease toll worldwide, expert warns
A Policy Shift Impacting Medical Coding in Healthcare
Health Policy Under The Trump Administration: The First 50 Days
Republicans can’t meet budget target without Medicaid cuts: CBO
Opinion: Tariffs will make it even more expensive for Americans to eat healthy

Share This Article